12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday’s regular session. The company’s market…
S&P 500 Edges Higher; America’s Car-Mart Shares Tumble After Q4 Earnings
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.1% on Tuesday.…
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday’s session after the company reported worse-than-expected FY24 financial results…
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday’s regular session. The company’s market…
Crude Oil Rises 1%; DermTech Shares Plummet
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 0.1% on Tuesday.…
What’s Going On With Taysha Gene Therapies Stock Tuesday?
Taysha Gene Therapies reveals promising longer-term and initial clinical data from their REVEAL Phase 1/2 trials evaluating TSHA-102 for Rett syndrome.
Taysha Gene Therapies Announced Longer-term Clinical Data From Ongoing REVEAL Phase 1/2 Adolescent And Adult Trial And Initial Clinical Data From REVEAL Phase 1/2 Pediatric Trial Of TSHA-102 In Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen
The Analyst Landscape: 16 Takes On Taysha Gene Therapies
Across the recent three months, 16 analysts have shared their insights on Taysha Gene Therapies (NASDAQ:TSHA), expressing a…
Breaking Down Taysha Gene Therapies: 16 Analysts Share Their Views
16 analysts have shared their evaluations of Taysha Gene Therapies (NASDAQ:TSHA) during the recent three months, expressing a…
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted By U.S. FDA For TSHA-102 In Rett Syndrome
RMAT designation follows FDA's review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT